For the PIK3CA gene, somatic copy number alterations in pre-treatment tumour biopsies included copy number gain in ~45% (10/22) or amplification in ~18% (4/22) of HER2+ breast cancer cases. This evidence concerns the gene PIK3CA and neoplasm.